Rallybio to Acquire Avenzo Therapeutics: Advancing Oncology Therapies

Rallybio has entered into an agreement to acquire Avenzo Therapeutics, a clinical-stage biotechnology company developing next-generation oncology therapies, through a merger transaction.

Upon closing, the combined company is expected to operate as Avenzo Therapeutics and trade on Nasdaq under the ticker symbol AVZO. A syndicate of leading health care institutional investors and mutual funds has committed to invest $215 million to support the advancement of multiple clinical milestones.

Ropes & Gray advised Rallybio in the transaction. The team was led by mergers & acquisitions partner Zach Blume and counsel Tyler Silvey and included employment, benefits, and executive compensation partner Renata Ferrari and tax partner Pamela Glazier.

#biotechnology #merger #oncology #AVZO #Nasdaq